Volume 1, Issue 12 July 2008
Patient information leaflets (PILs) are improving in quality as a result of new legal obligations on manufacturers to test the documents on potential patients. Testing makes sure that the presentation of the information enables patients to find and understand key messages for safe use about the medicine within the PIL and thereby enable them to use the medicine safely and effectively. To promote this new initiative, we are publishing a series of examples of best practice on our website. The latest in the series is the PIL for Aldactone (spironolactone), a diuretic for treatment of congestive heart failure and for oedema and ascites caused by cirrhosis of the liver.
Article citation: Drug Safety Update Jul 2008; Vol 1, Issue 12: 11